Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Buy" from Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are currently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year is $8.00.

SANA has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. JMP Securities reissued a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Finally, Morgan Stanley initiated coverage on shares of Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price on the stock.

Sana Biotechnology Stock Down 1.3%

Sana Biotechnology stock traded down $0.05 during mid-day trading on Monday, reaching $3.39. 1,040,738 shares of the company's stock traded hands, compared to its average volume of 5,943,798. The company has a market cap of $804.99 million, a price-to-earnings ratio of -3.19 and a beta of 1.90. The stock has a 50 day moving average of $3.55 and a two-hundred day moving average of $2.69. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. As a group, sell-side analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cerity Partners LLC bought a new position in shares of Sana Biotechnology in the fourth quarter worth about $25,000. Tower Research Capital LLC TRC grew its holdings in shares of Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock worth $25,000 after purchasing an additional 10,548 shares during the last quarter. Syon Capital LLC bought a new position in shares of Sana Biotechnology in the fourth quarter worth about $27,000. Ameriprise Financial Inc. bought a new position in shares of Sana Biotechnology in the fourth quarter worth about $29,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of Sana Biotechnology in the first quarter worth about $29,000. Hedge funds and other institutional investors own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.